Fulcrum Therapeutics' falling operating revenue and signific...

Fulcrum Therapeutics' falling operating revenue and significant cash burn relative to market value pose risks, despite a 13% cut in cash burn last year. The promising cash runway should be assessed against possible future fundraising costs.